Adecco Group AG (SWX:ADEN)
Switzerland · Delayed Price · Currency is CHF 25.02
+0.76 (3.13%)
Aug 6, 2025, 5:34 PM CET
Verve Therapeutics Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 22,925 | 23,138 | 23,957 | 23,640 | 20,949 | 19,561 | Upgrade | |
Revenue Growth (YoY) | -2.97% | -3.42% | 1.34% | 12.85% | 7.10% | -16.50% | Upgrade |
Cost of Revenue | 18,517 | 18,642 | 19,117 | 18,666 | 16,668 | 15,772 | Upgrade |
Gross Profit | 4,408 | 4,496 | 4,840 | 4,974 | 4,281 | 3,789 | Upgrade |
Selling, General & Admin | 3,752 | 3,813 | 3,990 | 4,164 | 3,346 | 3,217 | Upgrade |
Operating Expenses | 3,821 | 3,894 | 4,092 | 4,294 | 3,416 | 3,298 | Upgrade |
Operating Income | 587 | 602 | 748 | 680 | 865 | 491 | Upgrade |
Interest Expense | -69 | -73 | -77 | -49 | -32 | -30 | Upgrade |
Interest & Investment Income | 14 | 14 | 16 | 9 | 5 | 11 | Upgrade |
Earnings From Equity Investments | 41 | 35 | 23 | 30 | 23 | 20 | Upgrade |
Currency Exchange Gain (Loss) | -8 | -8 | -9 | -4 | -6 | -10 | Upgrade |
Other Non Operating Income (Expenses) | -48 | -35 | -51 | -49 | -8 | -4 | Upgrade |
EBT Excluding Unusual Items | 517 | 535 | 650 | 617 | 847 | 478 | Upgrade |
Merger & Restructuring Charges | -87 | -87 | -133 | -155 | -70 | - | Upgrade |
Impairment of Goodwill | - | - | - | - | - | -362 | Upgrade |
Gain (Loss) on Sale of Assets | - | - | - | - | 11 | -17 | Upgrade |
Asset Writedown | - | - | - | - | -31 | -27 | Upgrade |
Other Unusual Items | -5 | -5 | -10 | -11 | -4 | -4 | Upgrade |
Pretax Income | 425 | 443 | 507 | 451 | 753 | 68 | Upgrade |
Income Tax Expense | 136 | 140 | 180 | 106 | 165 | 165 | Upgrade |
Earnings From Continuing Operations | 289 | 303 | 327 | 345 | 588 | -97 | Upgrade |
Minority Interest in Earnings | 1 | - | -2 | -3 | -2 | -1 | Upgrade |
Net Income | 290 | 303 | 325 | 342 | 586 | -98 | Upgrade |
Net Income to Common | 290 | 303 | 325 | 342 | 586 | -98 | Upgrade |
Net Income Growth | -3.97% | -6.77% | -4.97% | -41.64% | - | - | Upgrade |
Shares Outstanding (Basic) | 168 | 168 | 167 | 167 | 162 | 161 | Upgrade |
Shares Outstanding (Diluted) | 168 | 168 | 168 | 167 | 163 | 162 | Upgrade |
Shares Change (YoY) | -0.12% | 0.19% | 0.57% | 2.67% | 0.44% | -0.33% | Upgrade |
EPS (Basic) | 1.73 | 1.81 | 1.94 | 2.05 | 3.62 | -0.61 | Upgrade |
EPS (Diluted) | 1.72 | 1.80 | 1.94 | 2.04 | 3.60 | -0.61 | Upgrade |
EPS Growth | -4.42% | -7.22% | -4.90% | -43.33% | - | - | Upgrade |
Free Cash Flow | 415 | 563 | 347 | 328 | 590 | 563 | Upgrade |
Free Cash Flow Per Share | 2.47 | 3.34 | 2.06 | 1.96 | 3.63 | 3.48 | Upgrade |
Dividend Per Share | 1.066 | 1.066 | 2.686 | 1.872 | 1.206 | 2.310 | Upgrade |
Dividend Growth | -60.32% | -60.32% | 43.48% | 55.27% | -47.80% | 0.42% | Upgrade |
Gross Margin | 19.23% | 19.43% | 20.20% | 21.04% | 20.43% | 19.37% | Upgrade |
Operating Margin | 2.56% | 2.60% | 3.12% | 2.88% | 4.13% | 2.51% | Upgrade |
Profit Margin | 1.26% | 1.31% | 1.36% | 1.45% | 2.80% | -0.50% | Upgrade |
Free Cash Flow Margin | 1.81% | 2.43% | 1.45% | 1.39% | 2.82% | 2.88% | Upgrade |
EBITDA | 713 | 748 | 916 | 875 | 984 | 627 | Upgrade |
EBITDA Margin | 3.11% | 3.23% | 3.82% | 3.70% | 4.70% | 3.21% | Upgrade |
D&A For EBITDA | 126 | 146 | 168 | 195 | 119 | 136 | Upgrade |
EBIT | 587 | 602 | 748 | 680 | 865 | 491 | Upgrade |
EBIT Margin | 2.56% | 2.60% | 3.12% | 2.88% | 4.13% | 2.51% | Upgrade |
Effective Tax Rate | 32.00% | 31.60% | 35.50% | 23.50% | 21.91% | 242.65% | Upgrade |
Updated Mar 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.